Hepatocellular Carcinoma Management
Hepatocellular carcinoma management is based on tumor stage, liver function, performance status, and treatment feasibility [1]. Management integrates locoregional therapy for potentially curable disease, systemic therapy for unresectable advanced disease, and supportive care for all stages [1].
Initial Diagnostic and Staging Workup
A diagnosis of hepatocellular carcinoma should follow guideline-based imaging and clinical criteria, typically using LI-RADS for at-risk patients [1].
Baseline staging should include evaluation of:
- Tumor extent and vascular invasion using cross-sectional imaging [1].
- Liver function using Child-Pugh class and assessment of portal hypertension when available [1].
- Performance status and cancer-related symptoms to guide eligibility for curative therapy versus palliative strategies [1].
Resectable Disease Management
Liver resection is considered for patients with preserved liver function and resectable tumor burden [1].
Perioperative evaluation and liver reserve assessment are required to minimize postoperative liver failure risk [1].
Selection should account for feasibility of complete resection with adequate remnant liver and acceptable operative risk [1].
Liver Transplantation Management
Liver transplantation is used as a potentially curative option for patients meeting transplant criteria and without contraindications to transplant [1].
Bridging locoregional therapy is commonly used while awaiting transplant to limit waitlist progression [1].
Curative-Intent Locoregional Therapy Management (Ablation and Locoregional Procedures)
Thermal ablation is considered for selected early hepatocellular carcinoma based on lesion size, number, and location [1].
Transarterial therapies are used for patients in whom cure by resection or ablation is not feasible, including transarterial chemoembolization and related approaches [1].
Response assessment after locoregional therapy should use cross-sectional imaging over time and should prompt escalation or conversion to alternative therapies when progression occurs [1].
Locoregional vs Systemic Therapy Decision Framework
Patients with early disease and adequate liver reserve are managed with curative-intent strategies when technically feasible [1].
Patients with unresectable disease, advanced tumor extent, or non-candidacy for locoregional control are managed with systemic therapy [1].
Treatment selection should incorporate liver function and performance status to avoid unsafe systemic exposure in decompensated patients [1].
Systemic Therapy Selection for Unresectable Advanced HCC
First-line systemic therapy selection is guided by trial evidence, liver function, and comorbidity-related contraindications [1].
Immune checkpoint inhibitor plus anti-VEGF therapy
- Atezolizumab plus bevacizumab is a preferred first-line option for unresectable advanced hepatocellular carcinoma in many patients based on improved survival versus sorafenib [1], [2].
Dual immune checkpoint inhibitor option
- Tremelimumab plus durvalumab is supported by phase 3 HIMALAYA results versus sorafenib, including OS benefit [1], [3].
Monotherapy vs Combination Therapy
Combination immunotherapy plus VEGF is used as combination therapy in appropriate first-line settings because randomized trials demonstrate survival benefit compared with sorafenib [2].
Dual checkpoint blockade is also used as combination therapy in eligible patients based on randomized phase 3 evidence versus sorafenib [3].
Single-agent checkpoint inhibitor therapy is commonly reserved for later lines or when combination therapy is not suitable based on contraindications and tolerability [1].
Key Evidence Supporting Major First-Line Systemic Choices
Atezolizumab plus bevacizumab improved overall survival compared with sorafenib in IMbrave150 [2].
IMbrave150 also improved progression-free survival compared with sorafenib [2].
HIMALAYA demonstrated overall survival benefit with tremelimumab plus durvalumab versus sorafenib in unresectable advanced hepatocellular carcinoma [3].
Treatment Monitoring and Ongoing Management
Treatment response should be assessed with interval cross-sectional imaging based on protocolized schedules after systemic or locoregional therapy [1].
Progression should trigger reassessment of disease extent, liver reserve, performance status, and eligibility for alternative locoregional or systemic strategies [1].
Supportive care should be incorporated throughout management, including management of cirrhosis complications and symptom-directed care [1].